News

MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial
US-based MAIA Biotechnology has dosed the first subject in Taiwan in the expansion phase of its multicentre THIO-101 Phase II ...
PipelineReview.com2d
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
CHICAGO, IL, USA I July 09, 2025 I MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company focused on developing targeted ...
IEEE3d
Visible-Infrared Person Re-Identification With Real-World Label Noise
In recent years, growing needs for advanced security and traffic management have significantly heightened the prominence of the visible-infrared person re-identification community (VI-ReID), garnering ...